Page 7 - Manip Nestor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Manip nestor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Manip Nestor Today - Breaking & Trending Today

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Sells $3,272,461.50 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) CEO Nikhil Lalwani sold 56,666 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $57.75, for a total value of $3,272,461.50. Following the completion of the sale, the chief executive officer now owns […] ....

United States , Nikhil Lalwani , Pharmaceuticals Trading , Oregon Public Employees Retirement Fund , Pharmaceuticals Inc , Pharmaceuticals Daily , Charles Schwab Investment Management Inc , Ani Pharmaceuticals Inc , Yousif Capital Management , Pharmaceuticals Company Profile , Get Free Report , Public Employees Retirement Fund , Schwab Investment Management , Capital Management , Ani Pharmaceuticals , Nasdaq Anip , Insider Trading , Nsider Trades ,

Chad Gassert Sells 20,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $51.06, for a total value of $1,021,200.00. Following the sale, the senior vice president now directly owns 333,226 shares in the […] ....

Nova Scotia , United States , Ani Pharmaceuticals Inc , Phocas Financial Corp , Pharmaceuticals Company Profile , Goldman Sachs Group Inc , Blackrock Inc , Balyasny Asset Management , Pharmaceuticals Inc , Pharmaceuticals Daily , Pharmaceuticals Price Performance , Get Free Report , Chad Gassert , Truist Financial , Capital Management , Asset Management , Sachs Group , Phocas Financial , Ani Pharmaceuticals , Nasdaq Anip , Insider Trading , Nsider Trades ,

Guggenheim Raises ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $62.00

ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) had its price objective raised by Guggenheim from $59.00 to $62.00 in a research note issued to investors on Thursday morning, FlyOnTheWall reports. Other equities research analysts also recently issued research reports about the company. Truist Financial upped their target price on ANI Pharmaceuticals from $52.00 to $60.00 and […] ....

United States , Zurcher Kantonalbank Zurich Cantonalbank , Muthusamy Shanmugam , Pharmaceuticals Trading , Ridgewood Investments , Securities Exchange Commission , Pharmaceuticals Daily , Dt Investment Partners , Pharmaceuticals Inc , Ani Pharmaceuticals , Lazard Asset Management , Free Report , Moderate Buy , Get Free Report , Exchange Commission , Asset Management , Kantonalbank Zurich Cantonalbank , Quantbot Technologies , Nasdaq Anip , Boost Price Target ,

ANI Pharmaceuticals (NASDAQ:ANIP) Price Target Raised to $60.00 at Truist Financial

ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) had its price target raised by Truist Financial from $52.00 to $60.00 in a research note released on Friday morning, Marketbeat.com reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. Several other research firms also recently weighed in on ANIP. StockNews.com downgraded shares of ANI […] ....

United States , Zurcher Kantonalbank Zurich Cantonalbank , Muthusamy Shanmugam , Ani Pharmaceuticals , Pharmaceuticals Inc , Dt Investment Partners , Ridgewood Investments , Lazard Asset Management , Pharmaceuticals Stock Performance , Pharmaceuticals Daily , Free Report , Truist Financial , Moderate Buy , Get Free Report , Asset Management , Kantonalbank Zurich Cantonalbank , Systematic Financial Management , Nasdaq Anip , Boost Price Target , Truist Financial Co ,

Muthusamy Shanmugam Sells 5,969 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) COO Muthusamy Shanmugam sold 5,969 shares of the business’s stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $51.48, for a total transaction of $307,284.12. Following the sale, the chief operating officer now owns 1,250,120 shares of […] ....

United States , Muthusamy Shanmugam , Zurcher Kantonalbank Zurich Cantonalbank , Pharmaceuticals Inc , Pharmaceuticals Daily , Lazard Asset Management , Ridgewood Investments , Pharmaceuticals Stock , Securities Exchange Commission , Dt Investment Partners , Ani Pharmaceuticals Inc , Get Free Report , Exchange Commission , Asset Management , Kantonalbank Zurich Cantonalbank , Quantbot Technologies , Ani Pharmaceuticals , Nasdaq Anip , Insider Trading , Nsider Trades ,